An FDA advisory committee disagreed with an earlier panel's recommendation and said children with attention deficit hyperactivity disorder and their parents need to be advised of risks of drugs for treating their condition, but a black-box warning is unnecessary. The latest panel's chairman said a redesign of drug labels to place important topics at the top could eliminate the need for the most-severe warnings.

Related Summaries